Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

MediciNova’s Drug Flunks Phase II Trial

La Jolla, Calif.-based MediciNova announced that the company’s Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.

Read More »

AnaptysBio’s Mid-Stage Peanut Allergy Data Indicates Positive Results

Shares of AnaptysBio climbed after the company released positive interim data for its experimental peanut allergy treatment.

Read More »

Clot-Busting Stroke Medicine: Mired in Controversy

An ischemic stroke occurs as a result of an obstruction within a blood vessel supplying blood to the brain and accounts for about 87 percent of all strokes, according to the American Stroke Association. A common treatment used to break up the clots and prevent brain damage has become mired in controversy.

Read More »

Esperion’s drug clears study as add-on cholesterol treatment

Esperion Therapeutics’ experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients who were already on another treatment to lower the risk of artery-clogging heart disease.

Read More »

Ablynx Lupus Drug Fails Again in Mid-Stage Trial

Ablynx’s anti-IL-6R nanobody vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.

Read More »

ImmunoGen Reports Positive Ovarian Cancer Data

ImmunoGen released positive efficacy and tolerability data from its FORWARD II trial of mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer.

Read More »

Protagonist Therapeutics Discontinues Phase IIb Ulcerative Colitis Study

Protagonist Therapeutics Inc. discontinued a Phase IIb study for the experimental ulcerative colitis treatment PTG-100 following a review from an Independent Data Monitoring Committee (DMC).

Read More »

Pfizer’s Chantix fails study in adolescent smokers

Pfizer Inc. said the company’s study to test safety and effectiveness of its anti-smoking treatment Chantix in adolescent smokers failed to meet the main goal.

Read More »

Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS

Novartis announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis were published in the peer-reviewed journal The Lancet.

Read More »

Array Touts Phase III Results for Melanoma Therapy

Shares of Array BioPharma Inc. climbed after the company released detailed results for its late-stage combination treatment for metastatic melanoma.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom